vimarsana.com
Home
Live Updates
GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other
GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other
GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other Benefits When Combined With Bortezomib
The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.
Related Keywords
,
Vitalii Vodolazskyi ,
Genzada Pharmaceuticals United States Inc ,
Impact Journals ,
Study Evaluating ,
Patients With Advanced Solid Tumors ,
Combination With Capecitabine ,
Genzada Pharmaceuticals United States ,